Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overcoming Key Operational Challenges in Integrating Bispecific Therapies
Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.
EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care
EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations
Now Viewing
EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies
EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology
EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies
EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions
EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration
EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies
EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies
EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?
Video content above is prompted by the following:
- What are the most common logistical challenges you encounter when implementing bispecific therapies?
- What are the primary barriers that smaller community practices face in operationalizing bispecific antibody treatments?
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
